Symbols / AVTX
AVTX Chart
About
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 309.44M |
| Enterprise Value | 182.71M | Income | -99.70M | Sales | 192.00K |
| Book/sh | 5.13 | Cash/sh | 6.16 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -3.67 | PEG | — |
| P/S | 1611.67 | P/B | 3.26 | P/C | — |
| EV/EBITDA | -2.76 | EV/Sales | 951.61 | Quick Ratio | 14.00 |
| Current Ratio | 14.28 | Debt/Eq | 0.61 | LT Debt/Eq | — |
| EPS (ttm) | -13.42 | EPS next Y | -4.55 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 07:00 | ROA | -37.18% |
| ROE | -174.79% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -346.32% | Profit Margin | 0.00% | Shs Outstand | 18.51M |
| Shs Float | 11.77M | Short Float | 17.28% | Short Ratio | 9.60 |
| Short Interest | — | 52W High | 20.72 | 52W Low | 3.39 |
| Beta | 0.89 | Avg Volume | 350.15K | Volume | 167.77K |
| Target Price | $36.11 | Recom | Strong_buy | Prev Close | $16.20 |
| Price | $16.71 | Change | 3.18% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$36.11
Mean price target
2. Current target
$16.72
Latest analyst target
3. DCF / Fair value
$-81.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$16.72
Low
$24.00
High
$50.00
Mean
$36.11
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-02 | init | Guggenheim | — → Buy | $50 |
| 2026-01-15 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-12-18 | init | Mizuho | — → Outperform | $39 |
| 2025-09-29 | reit | BTIG | Buy → Buy | $40 |
| 2025-09-17 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-08-15 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-03-25 | init | Jefferies | — → Buy | $23 |
| 2025-03-25 | init | Stifel | — → Buy | $36 |
| 2025-03-20 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-28 | init | Piper Sandler | — → Overweight | $48 |
| 2024-12-19 | init | BTIG | — → Buy | $40 |
| 2024-12-17 | init | LUCID CAPITAL MARKETS | — → Buy | $24 |
| 2024-10-24 | init | HC Wainwright & Co. | — → Neutral | — |
| 2024-04-16 | up | Oppenheimer | Perform → Outperform | $35 |
- TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity - Investing.com ue, 24 Feb 2026 15
- Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Sahm Mon, 02 Feb 2026 19
- $AVTX stock is down 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 01 Dec 2025 08
- Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains - simplywall.st ue, 16 Sep 2025 07
- We Think Avalo Therapeutics (NASDAQ:AVTX) Can Afford To Drive Business Growth - Yahoo Finance ue, 28 Oct 2025 07
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail Wed, 18 Feb 2026 08
- Would You Still Hold Avalo Therapeutics Stock If It Fell 30%? - Trefis ue, 23 Dec 2025 08
- What makes AVTX stock attractive today - July 2025 Opening Moves & Long Hold Capital Preservation Tips - mfd.ru Fri, 20 Feb 2026 15
- Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009’s LOTUS Results (NASDAQ:AVTX) - Seeking Alpha Mon, 18 Aug 2025 07
- Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) - Yahoo Finance Wed, 29 Oct 2025 07
- Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely? - simplywall.st Sat, 08 Nov 2025 08
- Piper Sandler Keeps Their Buy Rating on Avalo Therapeutics (AVTX) - The Globe and Mail hu, 05 Feb 2026 08
- New Analyst Forecast: $AVTX Given $25 Price Target - Quiver Quantitative hu, 15 Jan 2026 08
- Institutional investors own a significant stake of 34% in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Yahoo Finance Sun, 14 Sep 2025 07
- Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - Yahoo Finance hu, 06 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11367 | 162937.0 | — | Sale at price 14.30 - 14.35 per share. | GOLDMAN JONATHAN | Director | — | 2025-11-14 00:00:00 | D |
| 1 | 8200 | 81016.0 | — | Conversion of Exercise of derivative security at price 9.88 per share. | GOLDMAN JONATHAN | Director | — | 2025-11-14 00:00:00 | D |
| 2 | 3167 | nan | — | — | CHAN MITCHELL | Director | — | 2025-03-28 00:00:00 | D |
| 3 | 24200 | nan | — | — | SULLIVAN CHRISTOPHER RYAN | Chief Financial Officer | — | 2025-03-28 00:00:00 | D |
| 4 | 3167 | nan | — | — | KANTOFF AARON | Director | — | 2025-03-28 00:00:00 | D |
| 5 | 3167 | nan | — | — | TRUEX SAMANTHA | Director | — | 2025-03-28 00:00:00 | D |
| 6 | 3167 | nan | — | — | KAPLAN GILLA | Director | — | 2025-03-28 00:00:00 | D |
| 7 | 3167 | nan | — | — | ALMENOFF JUNE SHERIE | Director | — | 2025-03-28 00:00:00 | D |
| 8 | 3167 | nan | — | — | GOLDMAN JONATHAN | Director | — | 2025-03-28 00:00:00 | D |
| 9 | 64867 | nan | — | — | NEIL GARRY A. M.D. | Chief Executive Officer | — | 2025-03-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 6.34M | -971.67K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -98.53M | -18.66M | -37.27M | -80.48M |
| TotalUnusualItems | 30.18M | -4.63M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 30.18M | -4.63M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -35.13M | -31.54M | -41.66M | -84.35M |
| ReconciledDepreciation | 169.00K | 158.00K | 166.00K | 1.66M |
| ReconciledCostOfRevenue | -366.00K | 1.28M | 3.31M | 1.38M |
| EBITDA | -68.34M | -23.29M | -37.27M | -80.48M |
| EBIT | -68.51M | -23.44M | -37.44M | -82.13M |
| NetInterestIncome | 3.32M | -3.42M | -4.17M | -2.39M |
| InterestExpense | -3.32M | 3.42M | 4.17M | 2.39M |
| NormalizedIncome | -58.98M | -27.89M | -41.66M | -84.35M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -35.13M | -31.54M | -41.66M | -84.38M |
| TotalExpenses | 68.95M | 25.37M | 55.49M | 87.53M |
| TotalOperatingIncomeAsReported | -68.51M | -27.35M | ||
| DilutedAverageShares | 7.50M | 277.73K | 39.18K | 35.30K |
| BasicAverageShares | 4.43M | 277.73K | 39.18K | 35.30K |
| DilutedEPS | -20.91 | -113.58 | -1.06K | -2.39K |
| BasicEPS | -7.94 | -113.58 | -1.06K | -2.39K |
| DilutedNIAvailtoComStockholders | -35.13M | -31.54M | -41.66M | -84.38M |
| NetIncomeCommonStockholders | -35.13M | -31.54M | -41.66M | -84.38M |
| OtherunderPreferredStockDividend | -1.50M | |||
| NetIncome | -35.13M | -31.54M | -41.66M | -84.38M |
| NetIncomeIncludingNoncontrollingInterests | -35.13M | -31.54M | -41.66M | -84.38M |
| NetIncomeDiscontinuousOperations | 0.00 | -27.00K | ||
| NetIncomeContinuousOperations | -35.13M | -31.54M | -41.66M | -84.35M |
| TaxProvision | 114.00K | 14.00K | 28.00K | -196.00K |
| PretaxIncome | -35.02M | -31.53M | -41.63M | -84.55M |
| OtherIncomeExpense | 30.18M | -4.67M | -20.00K | -20.00K |
| OtherNonOperatingIncomeExpenses | -5.00K | -42.00K | -20.00K | -20.00K |
| SpecialIncomeCharges | -9.22M | -3.91M | 0.00 | 0.00 |
| OtherSpecialCharges | 9.22M | |||
| ImpairmentOfCapitalAssets | 0.00 | 3.91M | 0.00 | |
| RestructuringAndMergernAcquisition | 9.22M | 0.00 | ||
| GainOnSaleOfSecurity | 39.41M | -720.00K | ||
| NetNonOperatingInterestIncomeExpense | 3.32M | -3.42M | -4.17M | -2.39M |
| TotalOtherFinanceCost | -3.32M | 3.42M | 4.17M | 2.39M |
| InterestExpenseNonOperating | -3.32M | 3.42M | 4.17M | 2.39M |
| OperatingIncome | -68.51M | -23.44M | -37.44M | -82.13M |
| OperatingExpense | 69.32M | 24.08M | 52.06M | 86.04M |
| DepreciationAmortizationDepletionIncomeStatement | 0.00 | 38.00K | 1.55M | |
| DepreciationAndAmortizationInIncomeStatement | 0.00 | 38.00K | 1.55M | |
| Amortization | 0.00 | 38.00K | 1.55M | |
| AmortizationOfIntangiblesIncomeStatement | 0.00 | 38.00K | 1.55M | |
| ResearchAndDevelopment | 52.08M | 13.78M | 31.31M | 59.84M |
| SellingGeneralAndAdministration | 17.24M | 10.30M | 20.71M | 24.66M |
| SellingAndMarketingExpense | 789.00K | 33.00K | 76.00K | 1.66M |
| GeneralAndAdministrativeExpense | 16.45M | 10.27M | 20.64M | 23.00M |
| OtherGandA | 8.37M | 5.77M | 8.18M | 11.40M |
| SalariesAndWages | 8.08M | 4.50M | 12.46M | 11.60M |
| GrossProfit | 807.00K | 640.00K | 14.62M | 3.91M |
| CostOfRevenue | -366.00K | 1.28M | 3.43M | 1.49M |
| TotalRevenue | 441.00K | 1.92M | 18.05M | 5.40M |
| OperatingRevenue | 441.00K | 1.92M | 18.05M | 5.40M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 10.47M | 801.75K | 39.29K | 39.16K |
| ShareIssued | 10.47M | 801.75K | 39.29K | 39.16K |
| NetDebt | 6.24M | |||
| TotalDebt | 568.00K | 537.00K | 19.95M | 33.32M |
| TangibleBookValue | 122.53M | -3.20M | -25.32M | 8.63M |
| InvestedCapital | 133.03M | 7.30M | 8.50M | 55.91M |
| WorkingCapital | 131.93M | 3.78M | -5.70M | 41.96M |
| NetTangibleAssets | 122.53M | -3.20M | -25.32M | 8.63M |
| CapitalLeaseObligations | 568.00K | 537.00K | 532.00K | 485.00K |
| CommonStockEquity | 133.03M | 7.30M | -10.91M | 23.08M |
| TotalCapitalization | 133.03M | 7.30M | 2.57M | 55.91M |
| TotalEquityGrossMinorityInterest | 133.03M | 7.30M | -10.91M | 23.08M |
| StockholdersEquity | 133.03M | 7.30M | -10.91M | 23.08M |
| RetainedEarnings | -370.26M | -335.13M | -303.82M | -262.17M |
| AdditionalPaidInCapital | 503.29M | 342.44M | 292.91M | 285.24M |
| CapitalStock | 10.00K | 1.00K | 0.00 | 9.00K |
| CommonStock | 10.00K | 1.00K | 0.00 | 9.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 17.70M | 13.69M | 44.28M | 57.13M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.74M | 9.07M | 22.17M | 37.24M |
| OtherNonCurrentLiabilities | 2.35M | 3.37M | 3.71M | 4.30M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | ||
| DerivativeProductLiabilities | 8.12M | 5.55M | 4.83M | 0.00 |
| NonCurrentDeferredLiabilities | 270.00K | 155.00K | 141.00K | 113.00K |
| NonCurrentDeferredTaxesLiabilities | 270.00K | 155.00K | 141.00K | 113.00K |
| LongTermDebtAndCapitalLeaseObligation | 13.49M | 32.83M | ||
| LongTermDebt | 13.49M | 32.83M | ||
| CurrentLiabilities | 6.96M | 4.62M | 22.11M | 19.89M |
| OtherCurrentLiabilities | 360.00K | 480.00K | 9.00K | |
| CurrentDeferredLiabilities | 0.00 | 88.00K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 88.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 568.00K | 537.00K | 6.46M | 485.00K |
| CurrentCapitalLeaseObligation | 568.00K | 537.00K | 532.00K | 485.00K |
| CurrentDebt | 5.93M | |||
| OtherCurrentBorrowings | 5.93M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.88M | 580.00K | 2.70M | 4.31M |
| PayablesAndAccruedExpenses | 3.15M | 3.50M | 12.38M | 15.08M |
| CurrentAccruedExpenses | 2.54M | 3.06M | 8.99M | 11.34M |
| Payables | 610.00K | 446.00K | 3.39M | 3.74M |
| OtherPayable | 327.00K | 508.00K | 375.00K | |
| TotalTaxPayable | 0.00 | |||
| IncomeTaxPayable | 0.00 | |||
| AccountsPayable | 283.00K | 446.00K | 2.88M | 3.37M |
| TotalAssets | 150.73M | 20.99M | 33.37M | 80.21M |
| TotalNonCurrentAssets | 11.84M | 12.60M | 16.95M | 18.37M |
| OtherNonCurrentAssets | 131.00K | 131.00K | 131.00K | 1.23M |
| GoodwillAndOtherIntangibleAssets | 10.50M | 10.50M | 14.41M | 14.45M |
| OtherIntangibleAssets | 38.00K | |||
| Goodwill | 10.50M | 10.50M | 14.41M | 14.41M |
| NetPPE | 1.21M | 1.97M | 2.41M | 2.69M |
| AccumulatedDepreciation | -710.00K | -542.00K | -414.00K | -286.00K |
| GrossPPE | 1.92M | 2.51M | 2.83M | 2.98M |
| Leases | 1.64M | 2.23M | 739.00K | 739.00K |
| OtherProperties | 1.33M | 1.75M | 2.00M | |
| MachineryFurnitureEquipment | 282.00K | 282.00K | 336.00K | 241.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 138.89M | 8.39M | 16.42M | 61.84M |
| OtherCurrentAssets | 3.71M | 843.00K | 1.29M | 2.37M |
| RestrictedCash | 19.00K | 1.00K | 15.00K | 51.00K |
| PrepaidAssets | 2.37M | |||
| Inventory | 0.00 | 20.00K | 38.00K | |
| Receivables | 611.00K | 136.00K | 1.92M | 4.80M |
| OtherReceivables | 611.00K | 136.00K | 1.92M | 3.74M |
| AccountsReceivable | 0.00 | 1.06M | ||
| CashCashEquivalentsAndShortTermInvestments | 134.55M | 7.42M | 13.17M | 54.59M |
| CashAndCashEquivalents | 134.55M | 7.42M | 13.17M | 54.59M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -49.06M | -30.68M | -26.85M | -71.00M |
| RepurchaseOfCapitalStock | -14.81M | |||
| RepaymentOfDebt | 0.00 | -21.24M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 32.90M | ||
| IssuanceOfCapitalStock | 115.62M | 46.22M | 34.00K | 71.93M |
| CapitalExpenditure | -95.00K | -113.00K | ||
| InterestPaidSupplementalData | 0.00 | 1.93M | 2.93M | 1.58M |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 134.70M | 7.55M | 13.32M | 54.86M |
| BeginningCashPosition | 7.55M | 13.32M | 54.86M | 19.11M |
| ChangesInCash | 127.15M | -5.77M | -41.55M | 35.76M |
| FinancingCashFlow | 175.85M | 25.04M | -14.70M | 106.76M |
| CashFlowFromContinuingFinancingActivities | 175.85M | 25.04M | -14.70M | 106.76M |
| NetOtherFinancingCharges | -9.22M | |||
| ProceedsFromStockOptionExercised | 69.44M | 67.00K | 73.00K | 1.93M |
| NetCommonStockIssuance | 115.62M | 46.22M | -14.77M | 71.93M |
| CommonStockPayments | -14.81M | |||
| CommonStockIssuance | 115.62M | 46.22M | 34.00K | 71.93M |
| NetIssuancePaymentsOfDebt | 0.00 | -21.24M | 0.00 | 32.90M |
| NetLongTermDebtIssuance | 0.00 | -21.24M | 0.00 | 32.90M |
| LongTermDebtPayments | 0.00 | -21.24M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 32.90M | ||
| InvestingCashFlow | 356.00K | -133.00K | -95.00K | -113.00K |
| CashFlowFromContinuingInvestingActivities | 356.00K | -133.00K | -95.00K | -113.00K |
| NetOtherInvestingChanges | -158.00K | |||
| NetBusinessPurchaseAndSale | 356.00K | 0.00 | 0.00 | |
| SaleOfBusiness | 356.00K | 0.00 | 0.00 | |
| PurchaseOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | 0.00 | 25.00K | -95.00K | -113.00K |
| SaleOfPPE | 0.00 | 25.00K | 0.00 | |
| PurchaseOfPPE | 0.00 | -95.00K | -113.00K | |
| OperatingCashFlow | -49.06M | -30.68M | -26.75M | -70.89M |
| CashFlowFromContinuingOperatingActivities | -49.06M | -30.68M | -26.75M | -70.89M |
| ChangeInWorkingCapital | -4.71M | -9.24M | -60.00K | 2.84M |
| ChangeInOtherWorkingCapital | 70.00K | 88.00K | ||
| ChangeInOtherCurrentLiabilities | -88.00K | -76.00K | -9.00K | -45.00K |
| ChangeInOtherCurrentAssets | 0.00 | -1.00M | ||
| ChangeInPayablesAndAccruedExpense | -1.27M | -11.48M | -4.12M | 4.05M |
| ChangeInAccruedExpense | -1.11M | -9.05M | -3.63M | 3.25M |
| ChangeInPayable | -163.00K | -2.44M | -487.00K | 796.00K |
| ChangeInAccountPayable | -163.00K | -2.44M | -487.00K | 796.00K |
| ChangeInTaxPayable | 0.00 | 0.00 | ||
| ChangeInIncomeTaxPayable | 0.00 | 0.00 | ||
| ChangeInPrepaidAssets | -2.87M | 447.00K | 1.08M | 287.00K |
| ChangeInInventory | 0.00 | 20.00K | 18.00K | -35.00K |
| ChangeInReceivables | -475.00K | 1.78M | 2.88M | -414.00K |
| ChangesInAccountReceivables | 0.00 | 1.06M | 1.12M | |
| OtherNonCashItems | 24.05M | 1.83M | 1.39M | 794.00K |
| StockBasedCompensation | 5.85M | 3.48M | 7.55M | 8.17M |
| ProvisionandWriteOffofAssets | 1.00M | 0.00 | ||
| AssetImpairmentCharge | 0.00 | 3.91M | 0.00 | |
| DeferredTax | 114.00K | 14.00K | 28.00K | 22.00K |
| DeferredIncomeTax | 114.00K | 14.00K | 28.00K | 22.00K |
| DepreciationAmortizationDepletion | 169.00K | 158.00K | 166.00K | 1.66M |
| DepreciationAndAmortization | 169.00K | 158.00K | 166.00K | 1.66M |
| OperatingGainsLosses | -39.41M | 720.00K | 5.83M | |
| EarningsLossesFromEquityInvestments | 0.00 | |||
| GainLossOnInvestmentSecurities | -39.41M | 720.00K | 4.83M | |
| NetIncomeFromContinuingOperations | -35.13M | -31.54M | -41.66M | -84.38M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AVTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|